RenovoRx (NASDAQ:RNXT) Releases Earnings Results, Beats Estimates By $0.02 EPS

RenovoRx (NASDAQ:RNXT) posted its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02, FiscalAI reports. RenovoRx had a negative net margin of 823.98% and a negative return on equity of 135.03%.

Here are the key takeaways from RenovoRx’s conference call:

• Record revenue and upgraded guidance: Second-quarter revenue rose 61% sequentially and 115% year over year to $909,000, prompting RenovoRx to raise 2026 revenue guidance to $3.75 million–$4.25 million from $3 million–$4 million.
• Commercial expansion is accelerating: Active commercial cancer centers increased from 16 to 21 during the quarter, with 42 additional centers in the pipeline and a target of at least 36 active centers by year-end. Management said repeat orders and site conversions from the TIGeR-PaC trial should support another record revenue quarter in Q3.
• Clinical and product opportunity expanded: RenovoCath was used commercially for the first time in a sarcoma patient, providing physician-driven evidence of potential applications beyond locally advanced pancreatic cancer. Management also cited supportive clinical publications and growing physician advocacy.
• Phase III trial enrollment completed: The TIGeR-PaC study is nearly fully randomized, with 78 of the required 86 events reported as of August 11, 2026. Trial completion is expected in the first half of 2027, with initial topline data anticipated in the second half of 2027.
• Company remains loss-making and cash-constrained: RenovoRx reported a $3.4 million operating loss and held $9.5 million in cash at quarter-end. Although management expects cash to fund operations into the second half of 2027 and projects cash-flow break-even in Q4 2027, further capital could be needed if growth or trial timelines fall short.

RenovoRx Trading Down 2.6%

Shares of RNXT traded down $0.03 during mid-day trading on Wednesday, hitting $1.12. The company’s stock had a trading volume of 458,398 shares, compared to its average volume of 309,943. The company’s 50-day moving average is $0.93 and its 200-day moving average is $0.93. RenovoRx has a 52-week low of $0.70 and a 52-week high of $1.45. The firm has a market capitalization of $50.46 million, a price-to-earnings ratio of -3.39 and a beta of 0.99.

Hedge Funds Weigh In On RenovoRx

Institutional investors have recently bought and sold shares of the business. Bleichroeder LP raised its stake in RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after buying an additional 61,379 shares in the last quarter. Geode Capital Management LLC boosted its position in RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after acquiring an additional 31,730 shares in the last quarter. Wealthspire Advisors LLC bought a new stake in RenovoRx during the 4th quarter valued at $212,000. Citadel Advisors LLC purchased a new position in shares of RenovoRx in the 3rd quarter valued at $154,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in shares of RenovoRx in the 2nd quarter worth $98,000. 3.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RNXT has been the topic of several research reports. Ascendiant Capital Markets raised their price objective on RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Wall Street Zen upgraded RenovoRx from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.